918 Eli Lilly and Company $LLY Shares Sold by Perpetual Ltd

Key Points

• Perpetual Ltd. reduced its Eli Lilly stake by 15.5%, selling 918 shares and retaining 4,998 shares valued at approximately $5.8 million. Institutional investors collectively own 82.53% of Lilly.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $1,313.43; several firms recently raised or reiterated targets between $1,371 and $1,500.
• Lilly reported strong quarterly results, with EPS of $8.38 versus $6.40 expected and revenue up 47.7% year over year to $22.97 billion. However, shares opened down 1.3%, while insider selling and the company’s premium valuation remain potential investor concerns.

Perpetual Ltd decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 15.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,998 shares of the company's stock after selling 918 shares during the period. Perpetual Ltd's holdings in Eli Lilly and Company were worth $5,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $2,959,000. Mosaic Family Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Moran Wealth Management LLC grew its position in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock valued at $25,072,000 after purchasing an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC increased its holdings in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock valued at $12,258,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Amundi increased its holdings in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a "buy" rating in a report on Tuesday, September 15th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $1,500.00 target price on shares of Eli Lilly and Company in a research note on Monday. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a research note on Thursday, September 17th. Finally, Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Down 1.3%

LLY stock opened at $1,167.01 on Wednesday. The firm has a market cap of $1.10 trillion, a PE ratio of 37.56, a PEG ratio of 1.52 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm's 50 day moving average price is $1,176.60 and its 200-day moving average price is $1,102.08. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company's quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 34.79 EPS for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. 0.14% of the stock is owned by company insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its Eli Lilly earnings estimates to $36.55 per share for fiscal 2026 and $47.30 for 2027, modestly above its prior forecasts and the current consensus, signaling continued confidence in the company’s earnings momentum. Erste Group earnings estimates
• Positive Sentiment: Analysts continue to highlight Lilly’s rapid revenue and profit growth, supported by strong demand for diabetes and weight-loss medicines. Recent commentary suggests the company could raise its revenue outlook, while RBC reiterated an “outperform” rating and a $1,500 price target. Lilly growth and analyst outlook
• Positive Sentiment: Investors are focused on retatrutide, Lilly’s next-generation obesity candidate, which could potentially become a larger growth driver than Zepbound if clinical results support its efficacy and commercial viability. The company reports earnings on October 29, with updates on retatrutide likely to attract more attention than the quarterly results themselves. Retatrutide and upcoming earnings
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics on a Phase 1 breast-cancer trial evaluating PRT13722 with Verzenio and Inluriyo. Enrollment is expected to begin in the fourth quarter of 2026, adding another potential pipeline opportunity, although the program remains early stage. Prelude collaboration
• Neutral Sentiment: A Phase 3b study of Taltz combined with Zepbound showed improved skin clearance and weight loss in adults with plaque psoriasis and obesity, potentially supporting broader use of Lilly’s medicines, though the data are not yet a major revenue contributor. Taltz and Zepbound trial
• Negative Sentiment: Shares have pulled back amid profit-taking after a major run-up and concerns that Lilly’s premium valuation leaves less room for execution mistakes. The stock trades near record levels at roughly 39 times earnings, making upcoming guidance and pipeline updates especially important. Lilly stock pullback
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had substantially higher discontinuation rates, raising questions about tolerability and the eventual commercial potential of next-generation obesity therapies. Weight-loss combination study

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.